Navigation Links
Top-Line Preliminary Data From Phase II/III Study of Corthera's Relaxin in Acute Heart Failure to be Presented in Satellite Symposium at AHA Scientific Sessions 2008

SAN MATEO, Calif., Nov. 3 /PRNewswire/ -- Top-line preliminary data from a Phase II/III clinical trial of Corthera's investigational drug relaxin for the treatment of acute heart failure will be presented next week at a satellite symposium at the American Heart Association's (AHA) Scientific Sessions 2008 in New Orleans.

John R. Teerlink, M.D., Professor of Medicine, University of California San Francisco, will present the data from the multicenter, international Pre/RELAX-AHF study as part of a symposium entitled "Tailoring Therapy to Presentation" that will focus on new approaches to the treatment of acute heart failure. The symposium will take place from 6 a.m. CST to 8 a.m. CST on Monday, Nov. 10, in the Grand Ballroom of the Sheraton New Orleans Hotel.

According to the AHA, heart failure is a costly syndrome contributing to more than 3 million hospitalizations each year in the U.S. The great majority of patients with acute heart failure have fluid accumulation in the lungs (congestion) that causes shortness of breath and other complications. For these patients, the current standard of care includes diuretics and vasodilators. Both of these classes of agents have been associated with renal impairment, hypotension and adverse outcomes.

About Relaxin

Relaxin is a naturally occurring peptide hormone that acts as a systemic and renal vasodilator. Elevated levels of relaxin modulate increases in renal and cardiac function that meet the increased hemodynamic demands of pregnancy. Consistent with this natural role of the hormone, pharmaceutically manufactured relaxin has been shown to have these effects in multiple human studies of men and non-pregnant women. Data from a pilot study in patients with heart failure support the expectation that these effects may be beneficial in relieving the signs and symptoms of heart failure.

About Corthera

Corthera Inc. is a biopharmaceutical company committed to acquiring, developing and commercializing therapies for illnesses in the acute care setting. Corthera's lead product candidate, relaxin, is currently being evaluated in clinical trials for acute heart failure. Corthera has worldwide rights to develop and commercialize relaxin.

About the Satellite Symposium

Dr. Teerlink is the chair of the symposium and co-principal investigator of the Pre/RELAX-AHF study. Additional speakers will include Dr. Marco Metra, associate professor of cardiology, Department of Experimental and Applied Medicine, University of Brescia, Italy, and Dr. Gregg Fonarow, professor of medicine, UCLA School of Medicine. Dr. Metra is also co-principal investigator of the Pre/RELAX-AHF Study. Additional symposium information can be found at:

Contact: Andreas Marathovouniotis or Ian Stone

Russo Partners

212.845.4235 or 619.814.3510

SOURCE Corthera
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
2. Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer
3. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
5. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
6. CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Aidas Rh-Apo2L Clinical Testing Shows Preliminary Efficacy in Helping to Treat Lung Cancer, Stomach Cancer, Lymphoma, Pancreatic Cancer & Kidney Cancer
9. Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial
10. Symmetry Medical Reports Preliminary Third Quarter Revenue
11. KV Pharmaceutical Company Reports Record Revenues for Fiscal 2008 Second Quarter and Six Months on a Preliminary Basis
Post Your Comments:
(Date:11/24/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be ... York on Wednesday, December 2 at 9:30 a.m. ET/6:30 ... CEO, will provide a corporate overview. th Annual ... 1:00 p.m. ET/10:00 a.m. PT . Jim Mazzola , ... corporate overview. --> th Annual Oppenheimer Healthcare Conference ...
(Date:11/24/2015)... RALEIGH, N.C. , Nov. 24, 2015  Clintrax Global, Inc., ... Raleigh, North Carolina , today announced that the company has ... earnings represented a 391% quarter on quarter growth posted for Q3 ... Kingdom and Mexico , with the ... place in December 2015. --> United Kingdom ...
(Date:11/24/2015)... --> --> ... by Transparency Market Research, the global non-invasive prenatal testing ... 17.5% during the period between 2014 and 2022. The ... Analysis, Size, Volume, Share, Growth, Trends and Forecast 2014 ... to reach a valuation of US$2.38 bn by 2022. ...
(Date:11/24/2015)... ... November 24, 2015 , ... InSphero AG, the leading ... culture models, has promoted Melanie Aregger to serve as Chief Operating Officer. ... on the management team and was promoted to Head of InSphero Diagnostics ...
Breaking Biology Technology:
(Date:11/4/2015)... , November 4, 2015 ... market report published by Transparency Market Research "Home Security Solutions ... and Forecast 2015 - 2022", the global home security solutions ... bn by 2022. The market is estimated to expand ... from 2015 to 2022. Rising security needs among customers ...
(Date:10/29/2015)... 2015   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce that it has ... as one of only three finalists for a ... and Growing" category. The Tekne Awards honor Minnesota ... technology innovation and leadership. iMedNet™ eClinical ...
(Date:10/29/2015)... Va. , Oct. 29, 2015 Daon, ... today that it has released a new version of ... customers in North America have ... IdentityX v4.0 also includes a FIDO UAF certified ... are already preparing to activate FIDO features. These customers ...
Breaking Biology News(10 mins):